Melanoma

Dabrafenib Plus Trametinib Demonstrates Benefit in BRAF-Mutant Melanoma

June 23, 2020

Axel Hauschild, MD, PhD, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib and trametinib compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.

Fast Track Designation Granted to Seviprotimut-L Vaccine for Adjuvant Use in Stage IIB/IIC Melanoma

June 23, 2020

With a Fast Track designation, the development of seviprotimut-L will be facilitated and expeditiously reviewed by the FDA to address an unmet medical need for patients with stage IIB and IIIC melanoma,

3-Year Update Shows Continued Efficacy of Pembrolizumab for Melanoma

June 18, 2020

Alexander M. Eggermont, MD, PhD, discusses the results of the KEYNOTE 054 trial of pembrolizumab versus placebo in patients with high-risk stage III melanoma after a complete resection.

Prior ICI Associated With Longer PFS in BRAF V600E+ Melanoma Treated With Dabrafenib and Trametinib

June 04, 2020

"..These findings may be susceptible to selection bias since patients with more aggressive disease may be more likely to start dabrafenib and trametinib in the first line."

Autologous Tumor-Infiltrating Lymphocytes Effective for Treatment of Metastatic Melanoma

June 01, 2020

"We are very pleased to announce our pivotal cohort 4 early data from the C-144-01 clinical study in advanced melanoma today."

Survival Benefit Continues With Encorafenib Plus Binimetinib in BRAF V600E+ Melanoma

May 30, 2020

Encorafenib plus binimetinib show sustained overall survival and progression-free survival benefit in patients with BRAF V600–mutant melanoma, according to updated findings from the COLUMBUS study.

Long-Term Benefit of Dabrafenib Plus Trametinib in Melanoma Confirmed in 5-Year Follow-Up of COMBI-AD Study

May 30, 2020

The long-term benefit of adjuvant dabrafenib plus trametinib as treatment of patients with resected, stage III BRAF V600E/K-mutant melanoma were validated by 5-year data from the phase 3 COMBI-AD study.

The Importance of IMspire150 Data Is Questioned in Melanoma Treatment Landscape

May 27, 2020

Charles L. Sawyers, MD, discusses the value of atezolizumab, cobimetinib, and vemurafenib in the melanoma treatment landscape.

Patients in CheckMate 067 Demonstrate Durable Complete Responses

May 22, 2020

Georgina V. Long, BSc, PhD, MBBS, discusses the response rates in the CheckMate 067 trial, which evaluated the combination of ipilimumab and nivolumab in patients with advanced melanoma.

Pembrolizumab Plus Interleukin-12 Shows Activity in Metastatic Melanoma

May 08, 2020

"Combining pembrolizumab with Tavo electroporation improved responses for these patients who were predicted to have very poor responses to single-agent immune checkpoint inhibition."